LONDON - Microscience Ltd. is being acquired by U.S. company Emergent BioSolutions Inc. in an all-paper deal that values the vaccine specialist at £40 million (US$73.1 million), roughly £5 million less than the four venture capital investors have put in to date. (BioWorld International)

Cubist Pharmaceuticals Inc. said its Phase III trial with Cubicin (daptomycin) hit its primary endpoints against Staphylococcus aureus endocarditis and bacteremia, and the company has a supplementary new drug application in the works. (BioWorld Today)